- Home
- POR vs CYTK Comparison
POR vs CYTK Comparison
Compare POR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- CYTK
- Stock Information
- Founded
- POR 1889
- CYTK 1997
- Country
- POR United States
- CYTK United States
- Employees
- POR N/A
- CYTK N/A
- Industry
- POR Electric Utilities: Central
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- CYTK Health Care
- Exchange
- POR Nasdaq
- CYTK Nasdaq
- Market Cap
- POR 4.9B
- CYTK 5.0B
- IPO Year
- POR N/A
- CYTK 2004
- Fundamental
- Price
- POR $44.36
- CYTK $50.26
- Analyst Decision
- POR Hold
- CYTK Strong Buy
- Analyst Count
- POR 10
- CYTK 17
- Target Price
- POR $47.00
- CYTK $82.00
- AVG Volume (30 Days)
- POR 1.1M
- CYTK 1.9M
- Earning Date
- POR 02-14-2025
- CYTK 02-27-2025
- Dividend Yield
- POR 4.51%
- CYTK N/A
- EPS Growth
- POR 29.18
- CYTK N/A
- EPS
- POR 3.01
- CYTK N/A
- Revenue
- POR $3,440,000,000.00
- CYTK $3,219,000.00
- Revenue This Year
- POR N/A
- CYTK N/A
- Revenue Next Year
- POR $4.59
- CYTK $754.18
- P/E Ratio
- POR $14.74
- CYTK N/A
- Revenue Growth
- POR 17.69
- CYTK N/A
- 52 Week Low
- POR $39.49
- CYTK $40.53
- 52 Week High
- POR $49.85
- CYTK $81.36
- Technical
- Relative Strength Index (RSI)
- POR 67.31
- CYTK 58.40
- Support Level
- POR $41.32
- CYTK $45.05
- Resistance Level
- POR $41.94
- CYTK $48.30
- Average True Range (ATR)
- POR 0.81
- CYTK 2.80
- MACD
- POR 0.42
- CYTK 0.61
- Stochastic Oscillator
- POR 94.88
- CYTK 86.80
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.